Hot Features
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 fo... Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.13 | 1.02766798419 | 12.65 | 13.14 | 12.55 | 212216 | 12.83746435 | CS |
| 4 | -0.49 | -3.69253956292 | 13.27 | 13.6 | 11.4031 | 202591 | 12.48068663 | CS |
| 12 | -0.66 | -4.91071428571 | 13.44 | 14.7999 | 11.4031 | 293618 | 13.20779938 | CS |
| 26 | -59.36 | -82.2844469088 | 72.14 | 73.06 | 11.4031 | 1132341 | 56.39512069 | CS |
| 52 | -17.26 | -57.4567243675 | 30.04 | 73.06 | 11.4031 | 2560532 | 56.68114289 | CS |
| 156 | 1.44 | 12.6984126984 | 11.34 | 73.06 | 4.825 | 1689185 | 42.08595545 | CS |
| 260 | -16.44 | -56.2628336756 | 29.22 | 73.06 | 4.825 | 1300799 | 36.5957805 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.